Zobrazeno 1 - 10
of 50
pro vyhledávání: '"J. Skalweit"'
Autor:
Nora T. Oliver, Marion J. Skalweit
Publikováno v:
Infectious Disease Clinics of North America. 37:123-137
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6d69c48a369f983d640b7290e23d8c2
https://doi.org/10.1016/j.idc.2022.09.002
https://doi.org/10.1016/j.idc.2022.09.002
Autor:
Donald Dumford, Marion J. Skalweit
Publikováno v:
Infectious Disease Clinics of North America. 34:821-847
This article reviews antibiotic resistance and treatment of bacterial infections in the growing number of patients who are immunocompromised: solid organ transplant recipients, the neutropenic host, and persons with human immunodeficiency virus and A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72e5603adabb390e1b303ddaf1dc431a
https://doi.org/10.1016/j.idc.2020.08.005
https://doi.org/10.1016/j.idc.2020.08.005
Autor:
Mei Li, Marion J. Skalweit
Publikováno v:
Drug Design, Development and Therapy. 10:3013-3020
Genetic screening of Pseudomonas aeruginosa (PSDA) and Acinetobacter baumannii (ACB) reveals genes that confer increased susceptibility to β-lactams when disrupted, suggesting novel drug targets. One such target is lytic transglycosylase. Bulgecin A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::685181d4dff5aee0f2506c4dd1296c01
https://doi.org/10.2147/dddt.s110193
https://doi.org/10.2147/dddt.s110193
Autor:
Marion J. Skalweit
Publikováno v:
Advanced Concepts in Endocarditis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d1e64bd44706ea69f8de82c6cc3140c
http://www.intechopen.com/articles/show/title/left-ventricular-assist-device-infections
http://www.intechopen.com/articles/show/title/left-ventricular-assist-device-infections
Autor:
Khalid M, Dousa, Ahmed, Babiker, Daniel, Van Aartsen, Neel, Shah, Robert A, Bonomo, John L, Johnson, Marion J, Skalweit
Publikováno v:
Open Forum Infectious Diseases
Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase approved for the treatment of B-cell malignancies. There is growing concern about the risk of opportunistic infections following ibrutinib therapy. Herein, we describe the first cas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::392f196654ad541c2145c28c53b220b8
https://pubmed.ncbi.nlm.nih.gov/30090839
https://pubmed.ncbi.nlm.nih.gov/30090839
Autor:
Ahmed Babiker, Neel B Shah, Robert A. Bonomo, Khalid M Dousa, John L. Johnson, Marion J. Skalweit, Daniel Van Aartsen
Publikováno v:
Open Forum Infectious Diseases. 5
Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase approved for the treatment of B-cell malignancies. There is growing concern about the risk of opportunistic infections following ibrutinib therapy. Herein, we describe the first cas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5424aca4247bc250d1d82b7fd69a63e3
https://doi.org/10.1093/ofid/ofy168
https://doi.org/10.1093/ofid/ofy168
Autor:
Marion J. Skalweit, Shusuke Tomoshige, Shahriar Mobashery, Laura J. Rojas, David A Dik, Robert A. Bonomo
Publikováno v:
Open Forum Infectious Diseases
Background Genetic screening of ACB has revealed genes that confer increased susceptibility to β-lactams when these genes are disrupted suggesting novel drug targets. One such target is lytic transglycosylase, LT. Bulgecin A (BlgA) is a natural prod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41ab51ba5019ce890001b2475748e35c
http://europepmc.org/articles/PMC6811142
http://europepmc.org/articles/PMC6811142
Publikováno v:
Antimicrobial Agents and Chemotherapy. 59:1472-1477
Class C cephalosporinases are a growing threat, and inhibitors of these enzymes are currently unavailable. Studies exploring the YXN loop asparagine in the Escherichia coli AmpC, P99, and CMY-2 enzymes have suggested that interactions between C6′ o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7b5b7ecdca87eb51218d7c9637bf3c3
https://doi.org/10.1128/aac.03537-14
https://doi.org/10.1128/aac.03537-14